🇺🇸 Pyrimethamine/Sulfadiazine in United States

22 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 22

Most-reported reactions

1. Blastomycosis — 4 reports (18.18%)
2. Drug Ineffective — 4 reports (18.18%)
3. Superinfection Bacterial — 3 reports (13.64%)
4. Dermatitis Allergic — 2 reports (9.09%)
5. Maternal Exposure During Pregnancy — 2 reports (9.09%)
6. Off Label Use — 2 reports (9.09%)
7. Strongyloidiasis — 2 reports (9.09%)
8. Cholestatic Liver Injury — 1 report (4.55%)
9. Drug Reaction With Eosinophilia And Systemic Symptoms — 1 report (4.55%)
10. Dysphagia — 1 report (4.55%)

Source database →

Frequently asked questions

Is Pyrimethamine/Sulfadiazine approved in United States?

Pyrimethamine/Sulfadiazine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Pyrimethamine/Sulfadiazine in United States?

Assistance Publique - Hôpitaux de Paris is the originator. The local marketing authorisation holder may differ — check the official source linked above.